Atteinte pulmonaire au cours de la sclérodermie systémique. Partie II. Hypertension artérielle pulmonaire isolée, cancer bronchopulmonaire, hémorragie alvéolaire
Tóm tắt
Từ khóa
Tài liệu tham khảo
Arroliga, 1992, Pulmonary manifestations of scleroderma, J Thorac Imaging, 7, 30, 10.1097/00005382-199203000-00005
Black, 1996, Organ involvement: pulmonary, 299
Marie, 1999, Atteinte pulmonaire au cours de la sclérodermie systémique. Partie I. La pneumopathie interstitielle chronique fibrosante, Rev Méd Interne, 20, 1004, 10.1016/S0248-8663(00)87081-2
Silver, 1990, Lung involvement in systemic sclerosis, Rheum Dis Clin North Am, 16, 199, 10.1016/S0889-857X(21)01049-8
Silver, 1996, Scleroderma. Clinical problems. The lungs, Rheum Dis Clin North Am, 22, 825, 10.1016/S0889-857X(05)70303-3
Vallance, 1995, Immunosuppressive treatment of the pulmonary manifestations of progressive systemic sclerosis, Curr Opin Rheumatol, 7, 174, 10.1097/00002281-199505000-00004
Cherin, 1991, Hypertension artérielle pulmonaire et maladies systémiques, Rev Rhum (Ed Fr), 58, 387
LeRoy, 1991, Pulmonary hypertension: The bête noire of the diffuse connective tissue diseases, Am J Med, 90, 539
Lee, 1992, Mortality in systemic sclerosis (scleroderma), Q J Med, 82, 139
Parent-Woillez, 1997, L'hypertension artérielle pulmonaire primitive : une complication rare mais souvent mortelle du CREST syndrome, Rev Méd Interne, 18, 109, 10.1016/S0248-8663(97)84675-9
Morelli, 1997, Relationship between cutaneous and pulmonary involvement in systemic sclerosis, J Rheumatol, 24, 81
Koh, 1996, Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients, Br J Rheumatol, 35, 989, 10.1093/rheumatology/35.10.989
Menon, 1998, The acute effects of prostacyclin on pulmonary hemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis, Arthritis Rheum, 41, 466, 10.1002/1529-0131(199803)41:3<466::AID-ART13>3.0.CO;2-O
Sackner, 1964, The pathophysiology of scleroderma involving the heart and respiratory system, Ann Intern Med, 60, 611, 10.7326/0003-4819-60-4-611
Sfikakis, 1991, Cardiopulmonary hemodynamics in systemic sclerosis and response to nifedipine and captopril, Am J Med, 90, 541, 10.1016/0002-9343(91)90627-A
Steen, 1985, Pulmonary involvement in systemic sclerosis (scleroderma), Arthritis Rheum, 28, 759, 10.1002/art.1780280706
Stupi, 1986, Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis, Arthritis Rheum, 29, 515, 10.1002/art.1780290409
Ungerer, 1983, Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis, Am J Med, 75, 65, 10.1016/0002-9343(83)91169-5
Yousem, 1990, The pulmonary pathologic manifestations of the CREST syndrome, Hum Pathol, 21, 467, 10.1016/0046-8177(90)90002-M
Glikson, 1990, Nifedipine and prazosin in the management of pulmonary hypertension in CREST syndrome, Chest, 98, 759, 10.1378/chest.98.3.759
Salerni, 1977, Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma), Ann Intern Med, 86, 394, 10.7326/0003-4819-86-4-394
Thurm, 1991, Failure of vasodilator infusion to alter pulmonary diffusing capacity in systemic sclerosis, Am J Med, 90, 547, 10.1016/0002-9343(91)90628-B
Young, 1978, Pulmonary vascular changes in scleroderma, Am J Med, 64, 998, 10.1016/0002-9343(78)90455-2
Kharitonov, 1997, Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension, Thorax, 52, 1051, 10.1136/thx.52.12.1051
Owens, 1983, Pulmonary function in progressive systemic sclerosis: comparison of CREST syndrome variant with diffuse scleroderma, Chest, 84, 546, 10.1378/chest.84.5.546
Owens, 1987, Cardiopulmonary manifestations of systemic sclerosis, Chest, 91, 118, 10.1378/chest.91.1.118
Denton, 1997, Comparison of doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis, Br J Rheumatol, 36, 239, 10.1093/rheumatology/36.2.239
Trell, 1971, Pulmonary hypertension in systemic sclerosis, Ann Rheum Dis, 30, 390, 10.1136/ard.30.4.390
McCarthy, 1988, The lungs in systemic sclerosis (scleroderma): a review and new information, Semin Arthritis Rheum, 17, 271, 10.1016/0049-0172(88)90012-1
Peters-Golden, 1984, Carbon monoxide diffusing capacity as a predictor of outcome in systemic sclerosis, Am J Med, 77, 1027, 10.1016/0002-9343(84)90183-9
Peters-Golden, 1984, Clinical and demographic predictors of loss of pulmonary function in systemic sclerosis, Medicine, 63, 221, 10.1097/00005792-198407000-00004
Al-Sabbagh, 1989, Pulmonary arterial histology and morphometry in systemic sclerosis: a case-control autopsy study, J Rheumatol, 16, 1038
Sullivan, 1984, A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease, Medicine, 63, 92, 10.1097/00005792-198403000-00003
Alton, 1988, Lung involvement in scleroderma, 181
Steen, 1988, Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis, Arthritis Rheum, 31, 196, 10.1002/art.1780310207
Steen, 1998, Clinical manifestations of systemic sclerosis, Semin Cut Med Surg, 17, 48, 10.1016/S1085-5629(98)80062-X
Negi, 1998, Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension, J Rheumatol, 25, 461
Karmochkine, 1996, High prevalence of antiphospholipid antibodies in precapillary pulmonary hypertension, J Rheumatol, 23, 286
Briggs, 1991, Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis, Lancet, 338, 661, 10.1016/0140-6736(91)91235-M
Langevitz, 1992, HLA alleles in systemic sclerosis: association with pulmonary hypertension and outcome, Br J Rheumatol, 31, 609, 10.1093/rheumatology/31.9.609
LeRoy, 1996, Systemic sclerosis. A vascular perspective, Rheum Dis Clin North Am, 22, 675, 10.1016/S0889-857X(05)70295-7
Vancheeswaran, 1994, Circulating ET-1 levels in systemic sclerosis — A marker of fibrosis or vascular dysfunction, J Rheumatol, 21, 1838
Karmochkine, 1997, La thrombomoduline: physiologie et applications cliniques (en dehors des maladies systémiques), Rev Méd Interne, 18, 119, 10.1016/S0248-8663(97)84677-2
Seely, 1998, Systemic sclerosis: using high-resolution CT to detect lung disease in children, AJR, 170, 691, 10.2214/ajr.170.3.9490955
Steen, 1990, Pulmonary involvement in systemic sclerosis, 45
Steen, 1992, Isolated diffusing capacity reduction in systemic sclerosis, Arthritis Rheum, 35, 765, 10.1002/art.1780350709
Wilson, 1964, An early pulmonary physiologic abnormality in progressive systemic sclerosis (diffuse scleroderma), Am J Med, 36, 361, 10.1016/0002-9343(64)90162-7
Hyland, 1978, Effects of body position on carbon monoxide diffusing capacity in asymptomatic smokers and nonsmokers, Am Rev Respir Dis, 117, 1045
Barr, 1988, Reduction of pulmonary capillary blood volume following cold exposure in patients with Raynaud's phenomenon, Chest, 94, 1195, 10.1378/chest.94.6.1195
Furst, 1981, Abnormalities of pulmonary vascular dynamics and inflammation in early progressive systemic sclerosis, Arthritis Rheum, 24, 1403, 10.1002/art.1780241111
Gastaud, 1995, Short term effect of cold provocation on single-breath carbon monoxide diffusing capacity in subjects with and without Raynaud's phenomenon, Clin Exp Rheumatol, 13, 617
Miller, 1983, Effect of the cold pressor test on diffusing capacity: comparison of normal subjects and those with Raynaud's disease and progressive systemic sclerosis, Chest, 84, 264, 10.1378/chest.84.3.264
Naslund, 1981, A documented episode of pulmonary vasoconstriction in systemic sclerosis, Johns Hopkins Med J, 148, 78
Vergnon, 1992, Raynaud's phenomenon of the lung. A reality both in primary and secondary Raynaud's syndrome, Chest, 101, 1312, 10.1378/chest.101.5.1312
Wise, 1982, The effect of cold exposure on diffusing capacity in patients with Raynaud's phenomenon, Chest, 81, 695, 10.1378/chest.81.6.695
Shuck, 1985, Pulmonary vascular response during Raynaud's phenomenon in progressive systemic sclerosis, Am J Med, 78, 221, 10.1016/0002-9343(85)90430-9
Cailes, 1994, Correlation of echocardiography and right heart catheter in systemic sclerosis, Am J Respir Crit Care Med, 149, A43
Morgan, 1991, Hypoxic pulmonary vasoconstriction in systemic sclerosis and primary pulmonary hypertension, Chest, 99, 551, 10.1378/chest.99.3.551
Sfikakis, 1990, Diffusing capacity of the lung and nifedipine in systemic sclerosis, Arthritis Rheum, 33, 1634, 10.1002/art.1780331105
Gelber, 1995, Treatment of scleroderma, Curr Opin Rheumatol, 7, 551, 10.1097/00002281-199511000-00015
Pope, 1996, Scleroderma. Treatment of systemic sclerosis, Rheum Dis Clin North Am, 22, 893, 10.1016/S0889-857X(05)70307-0
Rich, 1992, The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension, N Engl J Med, 327, 76, 10.1056/NEJM199207093270203
Rich, 1994, Prostacyclin and primary pulmonary hypertension, Ann Intern Med, 121, 463, 10.7326/0003-4819-121-6-199409150-00012
Barst, 1994, Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin, Ann Intern Med, 121, 409, 10.7326/0003-4819-121-6-199409150-00003
Barst, 1996, A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension, N Engl J Med, 334, 296, 10.1056/NEJM199602013340504
De la Mata, 1994, Long-term Iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases, Arthritis Rheum, 37, 1528, 10.1002/art.1780371018
Fishman, 1998, Pulmonary hypertension — Beyond vasodilator therapy, N Engl J Med, 338, 321
Hinderliter, 1997, Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension, Circulation, 95, 1479, 10.1161/01.CIR.95.6.1479
McLaughlin, 1998, Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension, N Engl J Med, 338, 273, 10.1056/NEJM199801293380501
Olschewski, 1996, Aerosolized prostacyclin and Iloprost in severe pulmonary hypertension, Ann Intern Med, 124, 820, 10.7326/0003-4819-124-9-199605010-00006
Rubin, 1990, Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial, Ann Intern Med, 112, 485, 10.7326/0003-4819-112-7-485
Bartram, 1995, Use of intravenous prostacyclin to treat pulmonary hypertension associated with systemic sclerosis [abstract], Br J Rheumatol, 34, 30
Launay, 1998, Traitement de l'hypertension artérielle pulmonaire par aérosols d'Ilomédine compliquant la sclérodermie systémique, Rev Méd Interne, 19, 407s, 10.1016/S0248-8663(98)90080-7
Alpert, 1992, Short- and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease, Chest, 102, 1407, 10.1378/chest.102.5.1407
Baron, 1982, (a) Effects of prostaglandin E1 and other vasodilatator agents in pulmonary hypertension of scleroderma, Br Heart J, 48, 304, 10.1136/hrt.48.3.304
Niarchos, 1982, Hemodynamic effects of captopril in pulmonary hypertension of collagen vascular disease, Am J Heart, 104, 834, 10.1016/0002-8703(82)90020-5
Prouse, 1984, The CREST syndrome-successful reduction of pulmonary hypertension by captopril, Postgrad Med J, 60, 672, 10.1136/pgmj.60.708.672
Dahl, 1992, Ten year survival of a patient with advanced pulmonary hypertension and mixed connective tissue disease treated with immunosuppressive therapy, J Rheumatol, 19, 1807
Morelli, 1993, Pulmonary arterial hypertension responsive to immunosuppressive therapy in systemic lupus erythematosus, Lupus, 2, 367, 10.1177/096120339300200606
Tam, 1998, Successful treatment with immunosuppression, anticoagulation and vasodilator therapy of pulmonary hypertension in SLE associated with secondary antiphospholipid syndrome, Lupus, 7, 495, 10.1191/096120398678920442
Levine, 1994, Single lung transplantation in patients with systemic sclerosis, Chest, 105, 841, 10.1378/chest.105.3.837
Pigula, 1997, Lung transplantation for respiratory failure resulting from systemic disease, Ann Thorac Surg, 64, 1630, 10.1016/S0003-4975(97)00930-2
Bielefeld, 1996, Sclérodermie systémique et cancers: 21 observations et revue de la littérature, Rev Méd Interne, 17, 810, 10.1016/0248-8663(96)82683-X
Hatron, 1991, Sclérodermie systémique et cancer, Rev Méd Interne, 12, 331, 10.1016/S0248-8663(05)80840-9
Kyndt, 1997, Sclérodermie systémique et cancer. Recherche de facteurs prédictifs de cancer chez 123 patients sclérodermiques, Rev Méd Interne, 18, 528, 10.1016/S0248-8663(97)80804-1
Medsger, 1985, Systemic sclerosis and malignancy; are they related?, J Rheumatol, 12, 1041
Rosenthal, 1995, Incidence of cancer among patients with systemic sclerosis, Cancer, 76, 910, 10.1002/1097-0142(19950901)76:5<910::AID-CNCR2820760528>3.0.CO;2-T
Rosenthal, 1993, Scleroderma and malignancy: an epidemiologic study, Ann Rheum Dis, 52, 531, 10.1136/ard.52.7.531
Roumm, 1985, Cancer and systemic sclerosis. An epidemiologic study, Arthritis Rheum, 28, 1336, 10.1002/art.1780281204
Zatuchni, 1953, Pulmonary fibrosis and terminal bronchiolar (“alveolar-cell”) carcinoma in scleroderma, Cancer, 6, 1147, 10.1002/1097-0142(195311)6:6<1147::AID-CNCR2820060605>3.0.CO;2-L
Peters-Golden, 1985, Incidence of lung cancer in systemic sclerosis, J Rheumatol, 12, 1136
Talbott, 1980, Carcinoma of the lung in progressive systemic sclerosis: a tabular review of the literature and a detailed report of the roentgenographic changes in two cases, Semin Arthritis Rheum, 9, 191, 10.1016/0049-0172(80)90007-4
Talbott, 1979, Progressive systemic sclerosis (PSS) and malignancy, pulmonary and non-pulmonary, Medicine, 58, 182, 10.1097/00005792-197903000-00006
Salvant, 1988, CREST syndrome: a variant of progressive systemic sclerosis, associated with interstitial pulmonary fibrosis and malignancy, South Med J, 81, 1185, 10.1097/00007611-198809000-00030
Boehler, 1996, Bronchiolitis obliterans in a patient with localized scleroderma treated with D-penicillamine, Eur Respir J, 9, 1317, 10.1183/09031936.96.09061317
Camus, 1982, Manifestations respiratoires associées aux traitements par la D-pénicillamine, Rev Fr Mal Respir, 10, 7
Muir, 1997, Organizing diffuse alveolar damage associated with progressive systemic sclerosis, 72, 639
Vazquez-Del-Mercado, 1996, Diffuse alveolar hemorrhage in limited cutaneous systemic sclerosis with positive perinuclear antineutrophil cytoplasmic antibodies, J Rheumatol, 23, 1821
Endo, 1994, Anti-neutrophil cytoplasmic autoantibodies in 6 patients with renal failure and systemic sclerosis, J Rheumatol, 21, 864
Chausow, 1984, Reversible hypercapnic respiratory insufficiency in scleroderma caused by respiratory muscle weakness, Am Rev Respir Dis, 130, 142
Russell, 1981, Progressive generalized scleroderma: respiratory failure from primary chest wall involvement, Thorax, 39, 219, 10.1136/thx.36.3.219